Things aren't looking so hot for Brock Lesnar's MMA future, as according to the United States Anti-Doping Agency and the UFC, Lesnar failed a second drug test.
Lesnar originally failed a USADA administered test on June 28, and released a statement noting that "we will get to the bottom of this." According to a statement released by UFC, Lesnar failed for the same substance on July 9, the date of UFC 200, during an in-competition drug test.
“The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) has informed Brock Lesnar that his in-competition sample collection from July 9, 2016, at UFC 200, has tested positive for the same substance as his previously announced out-of-competition collection on June 28, 2016.
“USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case. It is important to note that, under the UFC Anti-Doping Policy, there is a full fair legal review process that is afforded to all athletes before any sanctions are imposed. The Nevada State Athletic Commission also retains jurisdiction over this matter as the sample collection was performed at UFC 200 in Las Vegas.
“Consistent with all previous potential anti-doping violations, additional information will be provided at the appropriate time as the process moves forward.”
Lance Pugmire of the L.A. Times revealed that he'd heard that Lesnar failed for clomiphene, an estrogen blocker. This is the same substance that Jon Jones was flagged for, and is often used when coming off of a cycle of PEDs.
Lesnar returned to the UFC after over four years out of the cage, and defeated top-10 heavyweight Mark Hunt, who is now demanding Lesnar's fight purse. It doesn't appear as if the drug tests will have any ramifications on Lesnar's planned pro wrestling match at Summerslam in New York, as the NYSAC doensn't individually license professional wrestlers.
By Sean Ross Sapp
